In this issue
Survival with adjuvant chemotherapy in early-stage NSCLC, with vs. without high-risk features
Neoadjuvant chemotherapy and nivolumab in resectable NSCLC
Brigatinib vs. crizotinib in advanced ALK inhibitor-naive ALK-positive NSCLC
Uncommon EGFR exon 19 insertion-deletion variants and EGFR-TKI efficacy in NSCLC
Safety of thoracic RT after immune-related adverse events from immune checkpoint inhibitors
Nivolumab + standard chemo-RT in locally advanced stage 3A/B NSCLC
Camrelizumab + apatinib in extensive-stage SCLC
Atezolizumab vs. docetaxel in pretreated NSCLC
Evidence for expanding invasive mediastinal staging for peripheral T1 lung tumours
Recruitment to a randomised trial of SBRT vs. surgery for peripheral stage 1 NSCLC
Please login below to download this issue (PDF)